Ignite Creation Date:
2025-12-26 @ 11:00 AM
Ignite Modification Date:
2026-01-01 @ 5:12 AM
Study NCT ID:
NCT06483906
Status:
RECRUITING
Last Update Posted:
2024-07-22
First Post:
2024-06-26
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML.
Sponsor:
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-07-02
Start Date Type:
ACTUAL
Primary Completion Date:
2026-07-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-07-01
Completion Date Type:
ESTIMATED
First Submit Date:
2024-06-26
First Submit QC Date:
None
Study First Post Date:
2024-07-03
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-07-19
Last Update Post Date:
2024-07-22
Last Update Post Date Type:
ACTUAL